The Use of tDCS in the Orofacial Pain
Orofacial Pain

About this trial
This is an interventional treatment trial for Orofacial Pain focused on measuring Orofacial Pain, tDCS, trancranial DIrect Current Stimulation, NIBS, non-invasive brain stimulation
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Orofacial Pain by a pain medicine specialist according to ICOP (International classification of orofacial pain) and ICHD3 (International classification of headache disorder)
- Stable analgesic therapy one month before the stimulation series
Exclusion Criteria:
- Changes to the analgesic therapy in 6 months following the stimulation series
- Non-compliance with the follow-ups
- General contraindications to tDCS - pregnancy, unstable cardiovascular disorders, epilepsy and intracranial masses
Sites / Locations
- Pain Management Centre, General University Hospital in Prague; Charles University in PragueRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Active group
Sham group
The investigators aim for six sessions of anodal stimulation over the right primary motor area contralateral to the orofacial pain (C3 or C4 in 10-20 EEG system) with cathode above the frontal area ipsilateral to the orofacial pain (Fp1 or Fp2) using HDCstim by Newronika S.r.l., Italy. The therapy will be administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 2 mA will be delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, anode 5x5cm, cathode 6x8cm, for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system will be used to determine the stimulation location, and dedicated EEG caps will be used to ensure consistency between applications.
The sham (placebo) will be administered using the same devices with a preprogrammed sham protocol (using HDCprog by Newronika S.r.l., Italy) of 20 minutes to be virtually indistinguishable from the active stimulation.